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 Background: Respiratory distress and patent ductus arteriosus (PDA) in neonates 
are mutually perpetuating. Contrary to the situation in premature infants, the rec-
ognition, clinical relevance and optimal management of PDA in full-term neonates 
are unclear. The present study aimed to identify PDA as a possible cause of respira-
tory distress in term and near-term neonates, and to examine the clinical responsive-
ness of PDA to different treatment modalities in mature-gestational-age neonates. 
 Methods: Patients with gestational ages of over 34 weeks were included in this retro-
spective chart review; they had PDA as the sole recognizable cause of respiratory 
distress and were free of all other diseases. Clinical responsiveness to different reg-
imens, including conservative treatment, drug therapy with preload reduction and ino-
tropic agent with or without the addition of indomethacin, and surgical intervention 
were analyzed.  
 Results: Forty-four neonates qualified for this study. Six received no treatment and 
their cardiorespiratory symptoms resolved within 1 week (regimen A). Symptoms in 
11 neonates were relieved after use of diuretic and inotropic agents (regimen B). 
Twelve neonates became asymptomatic without further intervention after indometh-
acin treatment in addition to preload reduction and inotropes (regimen C). A total 
of 15 of the 44 infants underwent PDA ligation (regimen D) due to persistent heart 
failure following regimens B or C, but had speedy resolution of respiratory symp-
toms following surgery. There were significant differences in birth body weight and 
hemodynamic variation based on left atrium to aortic root dimensional ratio between 
the treatment (regimens B, C and D) and non-treatment (regimen A) groups ( p  < 0.05). 
 Conclusion: PDA plays an important role in prolonging respiratory distress in term 
or near-term neonates. Although most infants respond to noninvasive medical treat-
ment, surgical ligation during the neonatal period is warranted in certain mature 
infants. Surgical treatment should be considered in patients with smaller birth 
body weights and those with increased left atrium to aortic root dimensional ratios. 
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 1. Introduction 
 Respiratory distress is a major issue in neonatal in-
tensive care units. It can be attributed to many 
causes, including pulmonary diseases, heart dis-
eases or central nervous system problems. In our 
clinical experience, respiratory distress in term or 
near-term neonates can result from delayed clo-
sure of patent ductus arteriosus (PDA). Physiologic 
closure of the ductus arteriosus relies on a postna-
tal increase in arterial oxygen tension and a de-
cline in pulmonary vascular resistance. In full-term 
neonates, functional closure of the ductus arteriosus 
occurs soon after birth; however, unstable perina-
tal conditions such as hypoxia or acidosis may lead 
to delayed closure. If the ductus arteriosus remains 
patent as the pulmonary vascular resistance falls, 
then aortic blood is shunted into the pulmonary ar-
tery, increasing pulmonary blood flow, and potentially 
causing pulmonary congestion and heart failure. Un-
like in premature infants, the clinical relevance and 
optimal management of PDA in term or near-term 
neonates with respiratory distress has been little 
studied. In this retrospective study, we reviewed 
the medical records from a tertiary medical center 
over a 3-year period. Analysis of its clinical course 
identified PDA as a possible cause of respiratory dis-
tress in term or near-term neonates. By comparing 
the different regimens including conservative treat-
ment, a combination of a diuretic (furosemide) and 
an inotropic agent (dopamine, dobutamine or milri-
none), the addition of indomethacin to the diuretic 
and inotropic regimen, and surgical intervention, 
we attempted to establish a guide for future man-
agement of PDA in term or near-term neonates 
with respiratory distress. The purpose of this study 
was therefore to identify PDA as a possible cause 
of respiratory distress in term or near-term neo-
nates, and to examine the clinical responsiveness 
of PDA to different treatment modalities in term 
or near-term neonates with respiratory distress.  
 2. Patients and Methods 
 2.1. Patients 
 A retrospective chart review of term or near-term 
neonates with PDA resulting in respiratory distress 
was conducted at a tertiary medical center over 
the 3-year period from 2004 to 2006. Patients in-
cluded in the study met all of the following four cri-
teria: (1) gestational age at birth ≥ 34 weeks; (2) 
symptoms of respiratory distress since birth requir-
ing ventilator support; (3) no definitive evidence 
of sepsis, pneumonia, meconium aspiration or pul-
monary air leak syndrome; and (4) existence of 
PDA with no other major cardiac anomalies as dem-
onstrated by echocardiography performed beyond 
72 hours of life. Patients were examined by a pedi-
atric cardiologist using two-dimensional echocar-
diography with color flow mapping (Philips Sonos 
7500 ultrasound with S8 Pediatric Cardiac Sector 
Probe; Royal Philips Electronics Inc., Amsterdam, the 
Netherlands) to assess ductal patency. Demographic 
data including sex, delivery method, gestational age, 
and birth body weight were recorded. Cardiac ul-
trasonography findings regarding PDA size and left 
atrium to aortic root dimensional ratio (LA/Ao) 
were recorded.  
 2.2. Treatments 
 The outcomes of the various clinical management 
regimens for PDA, including conservative treatment, 
diuretic and inotropic agents, addition of indometh-
acin to diuretic and inotropic agents, and surgical 
intervention were analyzed. Response to the man-
agement regimen was defined as improved cardio-
pulmonary status, disappearance of heart murmur 
or improved results on chest radiography. We clas-
sified patients into four groups depending on the ther-
apeutic regimens: (1) regimen A had spontaneous 
closure of PDA with conservative treatment; (2) regi-
men B included patients whose symptoms were re-
lieved after treatment with a diuretics (furosemide) 
and an inotropic agent (dopamine, dobutamine or 
milrinone); (3) regimen C included patients whose 
symptoms were controlled only after administra-
tion of indomethacin, diuretics and inotropes; (4) 
and regimen D required surgical ligation of PDA to 
resolve persistent heart failure. Patients were se-
lected for indomethacin treatment at the discretion 
of the attending neonatologist after a trial of furtile 
non-invasive medical treatment, and the absence of 
any contraindications, such as renal insufficiency and 
bleeding diathesis. Indomethacin was prescribed 
at a dose of 0.2−0.25 mg/kg intravenously at 12-hour 
intervals within 21 days of birth. Demographic data 
and hemodynamic variations in terms of the LA/Ao 
were compared between the four regimens. The pa-
tients were also divided into two categories based 
on non-treatment and treatment groups. The non-
treatment group was defined as those who experi-
enced spontaneous PDA closure with conservative 
treatment (regimen A), while the treatment group 
included those who required medical or surgical 
interventions prior to PDA closure (regimens B, C 
and D).  
 2.3. Statistical analysis 
 Demographic data and LA/Ao were compared among 
the four regimens using analysis of variance tests. 
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Comparisons between the non-treatment and treat-
ment groups were made using Student’s  t tests. 
Statistical significance was defined as  p ≤ 0.05. Data 
are expressed as  mean  ±  SD . All statistical analyses 
were performed using SPSS (SPSS Inc., Chicago, IL, 
USA). 
3.  Results 
 Forty-four patients qualified for this study over the 
3-year period. A total of 26 cases required mechani-
cal ventilator support; 8 cases needed non-invasive 
mechanical ventilation (nasal intermittent positive 
pressure ventilation using binasal prongs); 10 re-
ceived nasal continuous positive airway pressure 
support. The average arterial blood gas pH was 
7.329 ± 0.21. All neonates had PDA as the sole rec-
ognizable cause of respiratory distress, and were free 
of other illnesses. Of the 44 neonates, 6 received no 
treatment, and their cardiorespiratory symptoms 
resolved within 1 week (regimen A). Symptoms were 
relieved in 11 of the neonates after treatment with 
a diuretic (furosemide) and an inotropic agent 
(dopamine, dobutamine or milrinone) (regimen B). 
Fifteen of the patients received indomethacin treat-
ment in addition to preload reduction and inotropes, 
according to the discretion of the attending neo-
natologist. Three of these 15 infants had persis-
tent signs of congestive heart failure and went on 
to have surgical ligation of the ductus arteriosus, 
while 12 became symptom-free and needed no fur-
ther intervention (regimen C). However, of these 12 
infants, recurrent PDA was demonstrated by echocar-
diography at 3, 4 and 10 months of age. Therefore, 
only 60% (9/15) of patients were successfully treated 
by indomethacin with no reopening. A total of 15 of 
the 44 patients underwent PDA ligation (regimen D) 
after persistent heart failure following regimens B 
or C. Surgical ligation via thoracotomy was performed 
on postnatal day 17.4 ± 10.0 (mean ± SD ). All these pa-
tients had speedy resolution of respiratory symptoms 
after ligation, and were able to be weaned off me-
chanical ventilation. 
 Demographic data and LA/Ao are shown in Table 
1. The average LA/Ao ratios were 1.063 in regimen 
A ( n = 6), 1.156 in regimen B ( n = 11), 1.231 in regimen 
C ( n = 12) and 1.323 in regimen D ( n = 15). There was 
an apparent trend of increasing LA/Ao ratio with 
increasingly intensive or invasive treatment require-
ments. However, no significant differences in gesta-
tional age, birth body weight or LA/Ao were detected 
among the four regimens using analysis of variance 
tests ( p  > 0.05). 
 Differences in demographic data and hemody-
namic changes between the non-treatment and 
treatment groups were analyzed using Student’s  t 
tests. Mean gestational age, birth body weight and 
LA/Ao ratio in the non-treatment group were 
37.3  ±  1.8 weeks, 3220  ± 1056 g and 1.063, respec-
tively. Mean gestational age, birth body weight 
and LA/Ao ratio in the non-treatment group in the 
treatment group were 36.6  ± 1.9 weeks, 2623  ± 488 g 
and 1.236, respectively. There were significant dif-
ferences in birth body weight and hemodynamic 
variation (LA/Ao) between the non-treatment and 
treatment groups ( p  < 0.05). Patients with lower birth 
body weights and higher LA/Ao ratios needed fur-
ther management. Conversely, infants with higher 
body weights appeared to be more likely to have 
spontaneous resolution of their cardiopulmonary 
symptoms after their perinatal hypoxia and acido-
sis conditions subsided (Table 2). 
Table 1 Demographic data and left atrium-to-aortic root dimensional ratio (LA/Ao)
 Regimen A Regimen B Regimen C Regimen D 
 p
 
 ( n = 6) ( n = 11) ( n = 12) ( n = 15)
 Sex (M/F) 1/5 6/5 5/7 7/8  
 CS 2 8 4 8  
 GA (wk) 37.3 ± 1.8 37.6  ±  1.4 35.9  ± 2.1 36.4  ± 2.1 0.134 
 BW (g) 3220 ± 1056 2799  ± 253 2382  ± 547 2688 ± 663 0.073 
 LA/Ao 1.063 1.156 1.231 1.323 0.191 
 M = male; F = female; CS = cesarean section; GA = gestational age; BW = body weight. 
 Table 2  Comparison of demographic data and hemo-
dynamic changes between non-treatment 
group and treatment group 
 Non-treatment Treatment group  
p
 
 group ( n = 6) ( n = 38)
 LA/Ao 1.063 1.236  < 0.05 
 GA (wk) 37.3  ±  1.8 36.6  ± 1.9 0.403 
 BW (g) 3220 ± 1056 2623  ± 488  < 0.05 
LA/Ao = left atrium to aortic root dimensional ratio; GA = 
gestational age; BW = body weight.
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4.  Discussion 
 Closure of the ductus arteriosus is achieved by the 
contraction of the muscular media, which is the 
middle layer of the ductus composed of circumfer-
ential smooth muscle fibers. 1,2 The contraction of 
the media is triggered by high arterial oxygen con-
tent, a decline in pulmonary vascular resistance, and 
prostaglandin E2 in the circulation after birth. 3,4 In 
normal full-term neonates, functional closure of 
the ductus arteriosus occurs soon after birth; in 
contrast, delayed closure may occur in premature 
babies, because the muscular media of the ductus 
is inadequately developed and poorly responsive 
to high oxygen stimulation. 3,5 PDA occurs when the 
ductus arteriosus fails to close in postnatal life. 
PDA presents with low pulmonary vascular resistance 
and shunting of aortic blood into the pulmonary 
artery. Consequently, the inundation of pulmonary 
blood flow can lead to congestive heart failure, re-
sulting in pulmonary hypertension and pulmonary 
vascular obstructive disease (Eisenmenger’s syn-
drome). 6,7 PDA has also been associated with in-
creased neonatal morbidities, such as chronic lung 
disease, intraventricular hemorrhage and apnea. 8 
Other complications of untreated PDA include re-
current pneumonia, infective endocarditis, pulmo-
nary or systemic emboli, aneurysmal dilatation of 
the ductus and pulmonary hemorrhage. 9,10 If full-
term neonates suffer from hypoxia or acidosis, it 
may lead to delayed ductus arteriosus closure and 
subsequent heart failure. Delayed ductal closure 
often perpetuates hypoxia in neonates and vice 
versa. Unlike in premature infants, the clinical rel-
evance and optimal management of PDA in term or 
near-term neonates with respiratory distress has 
rarely been reported in the medical literature. This 
study attempted to evaluate the correlation be-
tween PDA and respiratory distress in full-term or 
near-term neonates. 
 We have occasionally encountered term or near-
term newborn infants who developed respiratory 
distress soon after birth, and PDA was shown to 
have played an important role in causing their res-
piratory symptoms. The presence of other pulmonary 
diseases, such as pneumonia, meconium aspiration, 
pulmonary air leak syndrome, congenital diaphrag-
matic hernia, chylothorax or pleural effusion, and 
major cardiac anomalies, including cyanotic or non-
cyanotic congenital heart diseases causing conges-
tive heart failure had been excluded in these cases, 
and PDA was recognized as the sole identifiable 
cause of respiratory distress in these term or near-
term neonates. We hypothesize that the neonates 
may have suffered from respiratory distress such as 
transient tachypnea of newborn soon after birth, 
and thus developed a persistently unstable perinatal 
condition. This unstable condition, in turn, resulted 
in hypoxia and acidosis that perpetuated pulmo-
nary resistance and hindered closure of the ductus 
arteriosus, causing subsequent congestive heart 
failure. Six of the 44 neonates in the current study 
received no medical treatment, while 11 of the 44 
were prescribed diuretic and inotropic agents. The 
cardiorespiratory compromise resolved promptly 
and the infants could be weaned off mechanical ven-
tilation. We therefore hypothesize that the ductus 
can close spontaneously, or with the help of medical 
treatment, after resolution of hypoxia or acidosis. 
 Previous studies found that the estimated inci-
dence of PDA in normal infants declined after 3 days 
of life. 5 Persistent PDA in term babies is due to a 
deficiency of the muscular media in the wall of the 
ductus. Thus, PDA rarely closes spontaneously or 
even following pharmacologic intervention in term 
babies, due to an uncorrected anatomical defect. 
In contrast, the patency in preterm babies is a result 
of hypoxia and immaturity of development. Indo-
methacin, an inhibitor of prostaglandin synthesis, 
can affect the smooth muscle tone of the ductus and 
promote ductal constriction. Indomethacin there-
fore plays an important role in pharmacologically 
assisted closure of PDA in premature infants. 11 The 
administration of indomethacin to term or near-term 
neonates with symptomatic PDA has rarely been 
described in the literature. In the present study, 
the management decision was at the discretion of 
the attending doctor from among the 10 neonatol-
ogists in our neonatal intensive care unit, and after 
a trial of futile non-invasive medical treatment in 
term babies who had PDA. Indomethacin was pre-
scribed in 15 cases. Twelve infants responded to in-
domethacin administration, while the remaining three 
required PDA ligation to relieve persistent signs of 
heart failure. Furthermore, indomethacin therapy 
is associated with an increased risk of re-opening 
of the ductus arteriosus, compared with surgery. 
Three of the 12 infants who initially responded to 
indomethacin had reopening, as shown by echocar-
diograms at 3, 4 and 10 months of age. Thus, only 60% 
(9/15) of patients were successfully treated by in-
domethacin with no recurrence. The latest Cochrane 
database review 12 reported that indomethacin was 
ineffective in up to 40% of patients. Moreover, the 
ductus re-opened in up to 35% of infants who ini-
tially responded to the drug. 12 In domethacin has 
been proven to be ineffective for the closure of 
the ductus arteriosus in infants of advanced post-
natal age. 13,14 Little et al 15 compared the merits of 
surgical ligation versus indomethacin treatment in 
pre-term and full-term infants with PDA. They re-
ported a recurrence rate of 47% after in domethacin 
treatment, and 60% of full-term infants underwent 
surgical ligation despite secondary indomethacin 
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administration. 15 Other investigations documented 
PDA recurrence rates after initial indo methacin re-
sponses of 43% and 40%, respectively. 16,17 Infants in 
whom the ductus was not constricted securely dur-
ing the initial use of indomethacin were also un-
likely to achieve permanent ductal closure during 
a second course of indomethacin treatment. 18 
 Indomethacin is an inhibitor of prostaglandin syn-
thesis, and a wide variety of adverse effects associ-
ated with its use particularly in preterm babies have 
been reported, including thrombocytopenia, bleed-
ing tendency, renal function impairment, oliguria, 
necrotizing enterocolitis, intestinal perforation, pul-
monary interstitial emphysema and intraventricu-
lar hemorrhage. 19 Although, some studies found no 
significant differences in the incidence of necrotizing 
enterocolitis, intraventricular hemorrhage and bron-
chopulmonary dysplasia between neonates treated 
with indomethacin and surgery, 15−20 the frequent 
complications, high recurrence rate, and greater 
morbidity and mortality associated with indometh-
acin therapy were emphasized. 15 −  20 In our study, 
the remaining 15 patients who had persistent signs 
of heart failure after regimens B and C needed sur-
gical ligation of PDA to resolve their respiratory dis-
tress and hemodynamic abnormalities. All of these 
patients had speedy resolution of their cardiopul-
monary symptoms after ligation, and were able to 
be weaned off mechanical ventilation. Overall, the 
results of surgical ligation were excellent, with lower 
morbidity and greater success. PDA ligation is there-
fore recommended as the preferred management 
strategy in full-term and near-term neonates. 15,16,21− 23 
 The prevalence of PDA is inversely related to 
gestational age and birth body weight. One of the 
major results of the current study demonstrated the 
significant differences in birth body weight and 
LA/Ao ratio between the treatment and non-treat-
ment groups. Little et al 15 also reported that a body 
weight  < 1000 g and a diameter of PDA  > 2.4 mm were 
significant predictors of indomethacin failure, sug-
gesting that direct ligation may be the best treat-
ment option in these patients. 15 Our results emphasize 
the need for further management strategies in pa-
tients with lower birth body weights and higher 
LA/Ao ratios. 
 This study was limited by its small case number, 
which reduced the power of the statistical analy-
sis, and by the lack of strict criteria for patients to 
go on indomethacin treatment. Apgar scores were 
unavailable in some cases, because many of them 
had been transferred to our hospital from local med-
ical clinics. Apgar scores can provide essential infor-
mation on the perinatal condition, which plays an 
important role in the development of PDA. A larger-
scale randomized controlled trial is needed to eval-
uate the clinical responsiveness of PDA to different 
treatment modalities in term or near-term ne-
onates with respiratory distress. 
5.  Conclusions 
 PDA plays a causative role in the development of 
respiratory distress in term or near-term neonates. 
Early accurate diagnosis and prompt optimal treat-
ment are necessary to prevent cardiorespiratory 
deterioration. Infants responded to conservative 
medical treatment after resolution of postnatal hy-
poxia and acidosis, but patients with lower birth 
body weights and increased LA/Ao ratios needed 
further management. Indomethacin is relatively in-
effective for ductal closure in term neonates, and 
surgical ligation during the neonatal period is war-
ranted in certain mature-gestational-age infants. 
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